Energesis Pharmaceuticals
Biopharmaceutical company developing therapeutics that increase brown adipose tissue mass to raise resting energy expenditure and produce fat-specific, sustainable weight loss. Uses a discovery platform based on adult human brown/beige adipocyte progenitor cells to identify targets and advance small‑molecule and biologic candidates from preclinical proof-of-concept toward early clinical studies. Maintains an IP portfolio and pursues partnerships for development and manufacturing.
Industries
Nr. of Employees
small (1-50)
Energesis Pharmaceuticals
Patents
Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US-11419916-B2
View DetailsBrown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor
US-8455204-B2
View Details
Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US-11419916-B2
View DetailsBrown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor
US-8455204-B2
View DetailsProducts
EGS-2632
Lead orally bioavailable combination candidate composed of two previously marketed drugs intended to increase brown adipocyte mass, raise resting energy expenditure, and produce fat-specific weight loss; being advanced toward Phase 1b/2a and Phase 2a proof-of-concept studies.
EGS-2632
Lead orally bioavailable combination candidate composed of two previously marketed drugs intended to increase brown adipocyte mass, raise resting energy expenditure, and produce fat-specific weight loss; being advanced toward Phase 1b/2a and Phase 2a proof-of-concept studies.
Expertise Areas
- Brown adipocyte discovery and adipogenesis
- Preclinical translational research measuring energy expenditure
- Oral small-molecule drug discovery for metabolic disease
- Early‑phase clinical development (Phase 1b/2a)
Key Technologies
- Human brown/beige adipocyte progenitor cell platform
- Adipogenesis screening assays
- UCP1 and thermogenic marker measurement
- In vivo energy expenditure and weight-change models
News & Updates
Strategic partnership with an animal-health company to license a biologic brown adipose tissue recruitment therapy for companion animals and to leverage partner CDMO capabilities for further development and manufacture.
Chief Scientific Officer provided insight into the potential for drugs enhancing energy expenditure as a next wave for obesity therapeutics.
U.S. Patent and Trademark Office issued a Notice of Allowance covering composition of matter and methods of use for the lead candidate, securing claimed protection expected into at least 2041.
Issued patent protecting methods of discovering compounds that create human brown adipocytes and methods to detect cellular differentiation into brown fat.
Awarded Phase 2 SBIR funding to support optimization and preclinical development of a protein therapeutic to recruit brown adipocytes.
Received NIH SBIR Phase 1 and Phase 2 grants and a Direct-to-Phase 2 award to support development of small molecules and protein therapeutics that promote brown adipogenesis and in vivo proof-of-concept.
Strategic partnership with an animal-health company to license a biologic brown adipose tissue recruitment therapy for companion animals and to leverage partner CDMO capabilities for further development and manufacture.
Chief Scientific Officer provided insight into the potential for drugs enhancing energy expenditure as a next wave for obesity therapeutics.
U.S. Patent and Trademark Office issued a Notice of Allowance covering composition of matter and methods of use for the lead candidate, securing claimed protection expected into at least 2041.
Issued patent protecting methods of discovering compounds that create human brown adipocytes and methods to detect cellular differentiation into brown fat.
Awarded Phase 2 SBIR funding to support optimization and preclinical development of a protein therapeutic to recruit brown adipocytes.
Received NIH SBIR Phase 1 and Phase 2 grants and a Direct-to-Phase 2 award to support development of small molecules and protein therapeutics that promote brown adipogenesis and in vivo proof-of-concept.